Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rodrigo Casasnovas Perera"'
Autor:
Anna Bochicchio, Sandra Jordaan, Valeria Losasso, Shivan Chetty, Rodrigo Casasnovas Perera, Emiliano Ippoliti, Stefan Barth, Paolo Carloni
Publikováno v:
Biomedicines, Vol 5, Iss 1, p 9 (2017)
Targeted human cytolytic fusion proteins (hCFPs) are humanized immunotoxins for selective treatment of different diseases including cancer. They are composed of a ligand specifically binding to target cells genetically linked to a human apoptosis-ind
Externí odkaz:
https://doaj.org/article/84a6e6881deb49c7ace63c399f423782
Autor:
Emiliano Ippoliti, Sandra Jordaan, Valeria Losasso, Paolo Carloni, Anna Bochicchio, Shivan Chetty, Rodrigo Casasnovas Perera, Stefan Barth
Publikováno v:
Biomedicines : open access journal 5(1), 9 (2017). doi:10.3390/biomedicines5010009 special issue: "Special Issue "Targeted Human Cytolytic Fusion Proteins" / Guest Editor Prof. Dr. Stefan Barth, Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, UCT, South Africa"
Biomedicines, Vol 5, Iss 1, p 9 (2017)
Biomedicines 5(1), 9 (2017). doi:10.3390/biomedicines5010009
Biomedicines
Biomedicines, Vol 5, Iss 1, p 9 (2017)
Biomedicines 5(1), 9 (2017). doi:10.3390/biomedicines5010009
Biomedicines
Biomedicines : open access journal 5(1), 9 (2017). doi:10.3390/biomedicines5010009 special issue: "Special Issue "Targeted Human Cytolytic Fusion Proteins" / Guest Editor Prof. Dr. Stefan Barth, Department of Integrative Biomedical Sciences, Institut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adec7a1b48255c36b3982aa9d11b3e62
https://doi.org/10.3390/biomedicines5010009
https://doi.org/10.3390/biomedicines5010009
Autor:
Nicolas Chatain, Paolo Carloni, Tim H. Brümmendorf, Rodrigo Casasnovas Perera, Janine Rossa, Steffen Koschmieder, Susanne Schnittger, Giulia Rossetti, Torsten Haferlach
Publikováno v:
ResearcherID
The survival of patients with acute myeloid leukemia (AML) is still poor, but recent advances including Fms-like tyrosine kinase 3 (FLT3) inhibitors are encouraging. Approximately 25 % of patients with AML carry an activating internal tandem duplicat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a64e2ddeb7d2dfd20e6ecdf1008f15ab
https://doi.org/10.1182/blood.v124.21.885.885
https://doi.org/10.1182/blood.v124.21.885.885